Difference between revisions of "Busulfan (Myleran)"

Revision as of 16:30, 30 November 2020

General information

Class/mechanism: Bifunctional alkylating agent which produces guanine-adenine intrastrand crosslinks, inducing apoptosis.^[1]^[2]^[3]^[4]
Route: IV, PO
Extravasation: irritant

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape,UpToDate (courtesy of Lexicomp), or the prescribing information.^[1]

Diseases for which it is used

Diseases for which it was used

Multiple myeloma

Patient drug information

History of changes in FDA indication

6/26/1954: Initial FDA approval
1/23/2003: (earliest label available at Drugs@FDA) indicated for the palliative treatment of chronic myelogenous (myeloid, myelocytic, granulocytic) leukemia.

Also known as

Brand names: Busulfex, Myleran

References

[insert-1] 1.0 ^1.1 Busulfan (Myleran) package insert

[2] Busulfan (Myleran) package insert (locally hosted backup)

[3] Busulfan (Busulfex) package insert

[4] Busulfan (Busulfex) package insert (locally hosted backup)

[5] Busulfan (Myleran) patient drug information (Chemocare)

[6] Busulfan (Myleran) patient drug information (UpToDate)

[1]

[2]

[3]

[4]

[5]

[6]

@@ Line 23: / Line 23: @@
 ==History of changes in FDA indication==
 * 6/26/1954: Initial FDA approval
+*1/23/2003: (earliest label available at Drugs@FDA) indicated for the palliative treatment of [[Chronic myelogenous leukemia|chronic myelogenous (myeloid, myelocytic, granulocytic) leukemia]].
 ==Also known as==